G.Barekat Pharm (XTEH:BRKT1) Gross-Profit-to-Asset % : 15.55% (As of Mar. 2017)

View and export this data going back to 2017. Start your Free Trial

What is G.Barekat Pharm Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. G.Barekat Pharm's annualized Gross Profit for the quarter that ended in Mar. 2017 was IRR5,413,825 Mil. G.Barekat Pharm's average Total Assets over the quarter that ended in Mar. 2017 was IRR34,818,314 Mil. Therefore, G.Barekat Pharm's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2017 was 15.55%.

G.Barekat Pharm Gross-Profit-to-Asset % Historical Data

The historical data trend for G.Barekat Pharm's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G.Barekat Pharm Gross-Profit-to-Asset % Chart

G.Barekat Pharm Annual Data

Trend

Mar16

Mar17

Gross-Profit-to-Asset %

15.55

G.Barekat Pharm Semi-Annual Data
	Mar16	Mar17
Gross-Profit-to-Asset %	-	15.55

Competitive Comparison of G.Barekat Pharm's Gross-Profit-to-Asset %

For the Biotechnology subindustry, G.Barekat Pharm's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

G.Barekat Pharm's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, G.Barekat Pharm's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where G.Barekat Pharm's Gross-Profit-to-Asset % falls into.

G.Barekat Pharm Gross-Profit-to-Asset % Calculation

G.Barekat Pharm's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2017 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Mar. 2017 )	/	( (Total Assets (A: Mar. 2016 )	+	Total Assets (A: Mar. 2017 ))	/ count )
	=	5413825	/	( (0	+	34818314)	/ 1 )
	=	5413825	/	34818314
	=	15.55 %

G.Barekat Pharm's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2017 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2017 )	/	( (Total Assets (Q: Mar. 2016 )	+	Total Assets (Q: Mar. 2017 ))	/ count )
	=	5413825	/	( (0	+	34818314)	/ 1 )
	=	5413825	/	34818314
	=	15.55 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is one times the annual (Mar. 2017) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

G.Barekat Pharm Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of G.Barekat Pharm's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

G.Barekat Pharm (XTEH:BRKT1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » G.Barekat Pharm (XTEH:BRKT1) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 11, 5th Alley, Bucharest Avenue, Argentina Square, Tehran, IRN

Website

http://www.bpharmed.com

G.Barekat Pharm focuses on the introduction of new pharmaceutical fields such as biotechnology, drug delivery which includes nanotechnology, slow release drugs, and new technologies for health, development of cellular molecular industries like tuberculosis, gene therapy, immunotherapy, and tissue technology.

G.Barekat Pharm (XTEH:BRKT1) Headlines

No Headlines